Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: Results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO

Blood

Volumn 97, Issue 10, 2001, Pages 2991-2997

  Mainwaring, Paul N ^a   Cunningham, David ^a   Gregory, Walter ^a   Hoskin, Peter ^a   Hancock, Barry ^a   Norton, Andrew J ^a   MacLennan, Ken ^a   Smith, Paul ^a   Hudson, Gillian Vaughan ^a   Linch, David ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; BLEOMYCIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; MITOXANTRONE; PREDNISOLONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; SURVIVAL TIME;

EID: 0035874527     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.10.2991     Document Type: Article

References (69)

1. d'Amore F, Brincker H, Christensen BE, et al. Non-Hodgkin's lymphoma in the elderly: a study of 602 patients aged 70 or older from a Danish population-based registry. The Danish LYEO-Study Group. Ann Oncol. 1992;3:379-386.
2. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non-Hodgkin's lymphoma. Cancer. 1997;80:2311-2320.
3. Weisenburger DD. Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol. 1994;5(suppl 1):19-24.
4. Wingo PA, Ries LA, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality, 1973-1995: a report card for the US. Cancer. 1998;82:1197-1207.
5. Skarin AT, Dorfman DM. Non-Hodgkin's lymphomas: current classification and management. CA Cancer J Clin. 1997;47:351-372.
6. Morgan G, Vornanen M, Puitinen J, et al. Changing trends in the incidence of non-Hodgkin's lymphoma in Europe. Biomed Study Group. Ann Oncol. 1997;8(supp) 2):49-54.
7. Connors JM, O'Reilly SE. Treatment considerations in the elderly patient with lymphoma. Hematol Oncol Clin North Am. 1997;11:949-961.
8. Tirelli U, Zagonel V, Monfardini S. Common errors in conducting and reporting clinical trials in non-Hodgkin lymphomas and patients' age [letter]. Eur J Cancer. 1991;27:811.
9. Ansell SM, Falkson G. A phase II trial of a chemotherapy combination in elderly patients with aggressive lymphoma [letter]. Ann Oncol. 1993;4:172.
10. Kovner F, Merimsky O, Inbar M, et al. Prognostic importance of advanced age in aggressive non-Hodgkin's malignant lymphoma. Oncology. 1996;53:435-440.
11. Salminen E. Age-related survival in non-Hodgkin's lymphoma. Oncology. 1998;55:7-9.
12. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
13. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project. Ann Oncol. 1997;8:973-978.
14. Ansell SM, Falkson G, van der Merwe R, Uys A. Chronological age is a multifactorial prognostic variable in patients with non-Hodgkin's lymphoma. Ann Oncol. 1992;3:45-50.
15. de Rijke JM, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, van den Brandt PA. Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol. 1996;7:677-685.
16. Repetto L, Venturino A, Vercelli M, et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 1998;82:760-765.
17. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival-a Groupe d'Etude des Lymphomes de I'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
18. Coiffier B. What treatment for elderly patients with aggressive lymphoma? [editorial]. Ann Oncol. 1994;5:873-875.
19. Goss PE. Non-Hodgkin's lymphomas in elderly patients. Leuk Lymphoma. 1993;10:147-156.
20. Martelli M, Guglielmi C, Coluzzi S, et al. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:2362-2369.
21. McMaster ML, Johnson DH, Greer JP, et al. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma. Cancer. 1991;67:1487-1492.
22. O'Reilly SE, Klimo P, Connors JM. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma. J Clin Oncol. 1991;9:741-747.
23. O'Reilly SE, Connors JM, Howdle S, et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol. 1993;11:2250-2257.
24. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
25. Tirelli U, Zagonel V, Errante D, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol. 1992;10:228-236.
26. Linch DC, Vaughan Hudson B, Hancock BW, et al. A randomised comparison of a third-generation regimen (PACEBOM) with a standard regimen (CHOP) in patients with histologically aggressive non-Hodgkin's lymphoma: a British National Lymphoma Investigation report. Br J Cancer. 1996;74:318-322.
27. Brusamolino E, Bertini M, Guidi S, et al. CHOP versus CNOP (N = mitoxantrone) in non-Hodgkin's lymphoma: an interim report comparing efficacy and toxicity. Haematologica. 1988;73:217-222.
28. Guglielmi C, Gherlinzoni F, Amadori S, et al. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas. Haematologica. 1989;74:563-569.
29. Pavlovsky S, Santarelli MT, Erazo A, et al. Results of a randomized study of previously-untreated intermediate and high grade lymphoma using CHOP versus CNOP. Ann Oncol. 1992;3:205-209.
30. Silver RT, Case DC, Wheeler RH, et al. Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease. J Clin Oncol. 1991;9:754-761.
31. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
32. Freedman LS. Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982;1:121-129.
33. 2 test. J R Stat Soc. 1934;1:217-235.
34. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
35. Cox DR. Regression models and life tables. J R Stat Soc. 1972;34:187-220.
36. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838-1844.
37. Tirelli U, Carbone A, Zagonel V, Veronesi A, Canetta R. Non-Hodgkin's lymphomas in the elderly: prospective studies with specifically devised chemotherapy regimens in 66 patients. Eur J Cancer Clin Oncol. 1987;23:535-540.
38. Zagonel V, Tirelli U, Carbone A, et al. Combination chemotherapy specifically devised for elderly patients with unfavorable non-Hodgkin's lymphoma. Cancer Invest. 1990;8:577-582.
39. Sonneveld P, Michiels JJ. Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer. 1990;62:105-108.
40. Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin: THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol. 1990;13(Suppl 1):S15-S19.
41. Watkin SW, Green JA. Non-Hodgkin's lymphoma: a four-drug regimen suitable for elderly patients with advanced disease. Acta Oncol. 1990;29:733-737.
42. Solal-Celigny P, Chastang C, Herrera A, et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med. 1987;83:1075-1079.
43. Tigaud JD, Demolombe S, Bastion Y, Bryon PA, Coiffier B. Ifosfamide continuous infusion plus etoposide in the treatment of elderly patients with aggressive lymphoma: a phase II study. Hematol Oncol. 1991;9:225-233.
44. Salvagno L, Contu A, Bianco A, et al. A combination of mitoxantrone, etoposide and prednisone in elderly patients with non-Hodgkin's lymphoma. Ann Oncol. 1992;3:833-837.
45. Cohn JB, Malavet AL, Tester WJ, et al. Chemotherapy in elderly patients with intermediate grade non-Hodgkin's lymphoma with weekly CNOP (cyclophosphamide, Novantrone, vincristine, prednisone) [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1993;12:A1253.
46. Zinzani PL, Bendandi M, Gherlinzoni F, et al. VNCOP-B regimen in the treatment of high-grade non-Hodgkin's lymphoma in the elderly. Haematologica. 1993;78:378-382.
47. Bessell EM, Coutts A, Fletcher J, et al. Non-Hodgkin's lymphoma in elderly patients: a phase II study of MCOP chemotherapy in patients aged 70 years or over with intermediate or high-grade histology. Eur J Cancer. 1994;30A:1337-1341.
48. Young WA, reco FA, Greer JP, Hainsworth JD. Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide. J Natl Cancer Inst. 1994;86:1346-1347.
49. Epelbaum R, Haim N, Leviov M, et al. Full dose CHOP chemotherapy in elderly patients with non-Hodgkin's lymphoma. Acta Oncol. 1995;34:87-91.
50. Goss P, Burkes R, Rudinskas L, et al. Aphase II trial of prednisone, oral etoposide, and novantrone (PEN) as initial treatment of non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma. 1995;18:145-152.
51. Karduss A, Gomez R, Cuellar F, et al. Evaluation of CNOP in patients over 60 years of age with non-Hodgkin's lymphoma [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1995;14:406.
52. Bertini M, Freilone R, Vitolo U, et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen. Leuk Lymphoma. 1996;22:483-493.
53. Bellesi G, Rigacci L, Alterini R, et al. A new protocol (MiCEP) for the treatment of intermediate or high-grade non-Hodgkin's lymphoma in the elderly. Leuk Lymphoma. 1996;20:475-480.
54. Caracciolo F, Petrini M, Capochiani E, Papineschi F, Carulli G, Grassi B. Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly. Hematol Oncol. 1994;12:185-192.
55. Merli F, Federico M, Avanzini P, et al. Weekly administration of vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the treatment of elderly aggressive non Hodgkin's lymphoma. Gruppo Italiano per lo Studio dei Linfomi. Haematologica. 1998;83:217-221.
56. Kimmick GG, Fleming R, Muss HB, Balducci L. Cancer chemotherapy in older adults: a tolerability perspective. Drugs Aging. 1997;10:34-49.
57. Ruckle H. CHOP vs CNOP in the treatment of diffuse non-Hodgkin's lymphomas, 2nd Nordic Novantrone Symp', 1988.
58. Fisher RI, Gaynor ER, Dahlberg S, et al. A phase III comparison of CHOP vs. m-BACOD vs. Pro-MACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994;5(suppl 2):91-95.
59. Bezwoda W, Rastogi RB, Erazo Valla A, et al. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate-and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group. Eur J Cancer. 1995;31A:903-911.
60. Haw R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to frontline chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol. 1994;12:1074-1084.
61. Gómez H, Hidalgo M, Casanova L, et al. Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis. J Clin Oncol. 1998;16:2065-2069.
62. Mounier N, Morel P, Haioun C, et al. A multivariate analysis of the survival of patients with aggressive lymphoma: variations in the predictive value of prognostic factors during the course of the disease. Groupe d'Etudes des Lymphomes de l'Adulte. Cancer. 1998;82:1952-1962.
63. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacokinetics and metabolism of mitoxantrone: a review. Clin Pharmacokinet. 1990;18:365-380.
64. Gams RA, Bryan S, Dukart G, et al. Mitoxantrone in malignant lymphoma. Invest New Drugs. 1985;3:219-222.
65. Posner LE, Dukart G, Goldberg J, Bernstein T, Cartwright K. Mitoxantrone: an overview of safety and toxicity. Invest New Drugs. 1985;3:123-132.
66. Case DC, Wolff S, Bennett J, et al. Phase III comparative trial of M-B-adriamycin COD (M-BACOD) V. M-B-novantrone COD (M-BNCOD) in the treatment of intermediate high grade lymphoma. Blood. 1988;72(suppl 1):868.
67. Epelbaum R, Faraggi D, Ben A-Y, et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. Cancer. 1990;66:1124-1129.
68. Pettengell R, Crowther D. Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma. Ann Oncol. 1994;5(suppl 2):133-141.
69. Meyer RM, Hrynluk WM, Goodyear MD. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma. J Clin Oncol. 1991;9:339-347.